Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

This study is looking for adults aged 18 or over. In the first part of the study, we are looking for people with non-small cell lung cancer, stomach cancer, head and neck cancer, or a type of throat cancer (oesophageal squamous cell carcinoma) who have already tried standard treatments, and these treatments either didn't work for them or they couldn't tolerate them. You can have had many previous treatments, there isn't a limit.

In the second part of the study, we are looking for people with non-small cell lung cancer, head and neck cancer, or other types of solid tumours, where your doctor has identified specific changes in your cancer cells (called applicable mutations).

To join, you'll need to provide a sample of your cancer tissue. Your cancer must be measurable on scans, and you should be generally well enough to take part in daily activities (we use a special scale for this, and you'd need to meet specific criteria). We also need to be sure your body's organs are working properly, and your doctor thinks you are likely to live for at least 12 weeks. There are some specific health conditions that would prevent you from joining, such as untreated brain tumours or having had major surgery or radiotherapy too recently.

If you join this study, you will receive the new study drug, MCLA-129. You'll have regular hospital visits for check-ups, scans, and blood tests to monitor your health and how your body is responding to the treatment. These visits will help us understand if the medicine is working and if there are any side effects. The study involves taking the medicine over a period and having follow-up appointments. The exact number of visits and the total length of time you'll be in the study will depend on which part of the study you are in and how you respond to the treatment. Your study team will explain everything to you in detail.